Graft-versus-host disease (GVHD) induced by transplant-derived T cells represents a major complication after allogeneic bone marrow transplantation (BMT). These T cells, however, support engraftment, early T cell immunity and mediate the graft-versus-tumor (GVT) effect.
Introduction
Allogeneic bone marrow transplantation (BMT) is a potentially curative treatment modality for hematological malignancies, which involves the graft-versus-tumor or graft-versusleukemia effect i.e. elimination of residual tumor cells by mature allogeneic T cells in the transplant. These T cells, however, are also responsible for the induction of graft-versus-host disease (GVHD), which is still a major complication after allogeneic BMT leading to significant morbidity and mortality despite routine immune suppression used in all protocols. 1 T cell depletion of the graft significantly decreases the risk of GVHD, however it also delays engraftment, sensitizes the host for opportunistic infections and abrogates the GVT effect. 2 Therefore, preventing GVHD while maintaining GVT activity and early T cell immunity is a major goal in allogeneic BMT.
GVHD represents a complex disease depending on alloantigen-specific T cell activation, proliferation, and subsequent induction of T cell effector functions, which are attempt to be inhibited by routinely given immunosuppressive therapy. This, however, causes general immunosuppression leading to an increased risk for opportunistic infections, cancer development and also severely suppresses the GVT effect. 3 Acquiring effector functions is associated with versatile molecular and cellular changes in the T cell e.g. the expression of activation markers, homing molecules, cytokines and cytotoxic molecules which represent possible targets for new therapeutic approaches in GVHD-prevention and -treatment. 4 Analysis of T cell subsets showed that memory T cells are unable to induce GVHD but efficiently eradicate tumor cells. 5, 6 We recently found that even in vitro-generated alloantigenspecific cytotoxic T cells (CTLs) mediate anti-tumor cytotoxicity in the absence of GVHD. 7 Interfering with T cell trafficking or cytokine production offers other treatment strategies. 8, 9 The primary goal of most trials is the inhibition of host tissue destruction by attacking alloantigen-specific T cells. Destructive function of T cells is mediated either by death ligands CD95L, TRAIL, and TNF-α or the perforin/granzyme system. BMT-models using T cells
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10-12 Efficient anti-tumor cytotoxicity, however, is predominantly dependent on TNF-α and perforin. 11, 13 The role of TRAIL in GVHD induction and GVT effect is controversially discussed. 5, 14, 15 These studies indicate that interference with the CD95/CD95L
pathway might be a successful treatment option to inhibit GVHD without abrogating the desired GVT effect after allogeneic BMT. APG101 is a human soluble fusion protein consisting of the extracellular domain of CD95 and the Fc portion of IgG1 thereby blocking the interaction of CD95L with its cognate receptor. APG101 has already been shown to be well tolerated up to high doses in a phase I first-in-man study 16 and may therefore be applicable in GVHD prophylaxis. Since the CD95 system can mediate other cellular functions in addition to apoptosis such as migration, invasiveness and tumor promotion dependent on the specific cellular systems 17, 18 , APG101 is also currently exploited in the treatment of gliomas. 19 To test, whether the CD95L-mediated inhibition of tissue destruction by APG101 offers a new therapeutic approach to treat and / or prevent GVHD, we treated allogeneic BMtransplanted mice on a regular basis with APG101. Since CD95L is not only known for its function as an apoptosis inducer, but may also transmit signals into the CD95L-expressing cells, a process known as reverse signaling and predominantly affecting T cell proliferation [20] [21] [22] , we further analyzed the effect of APG101 on T cell function, anti-tumor cytotoxicity and homing.
In a parent into F1 MHC class I and II-mismatched BMT model and a BMT model differing in minor histocompatibility antigens (miHAg), we found that APG101 efficiently prevents clinical, CD95L-mediated GVHD. APG101 inhibited CD95-mediated apoptosis without disabling T cell functions since donor-derived T cells maintained their migratory ability,
For personal use only. on . by guest www.bloodjournal.org From 5 proliferated after activation and most importantly exhibited efficient anti-tumor cytotoxicity with complete elimination of residual tumor cells. Thus, inhibiting CD95/CD95L interaction by APG101 might represent a clinically applicable strategy in allogeneic BMT to inhibit GVHD without disabling T cell functions indispensable for anti-tumor cytotoxicity and early T cell immunity.
For
Materials and Methods

Cell culture
All cell lines were grown in complete RPMI 1640 medium (GIBCO-BRL, United Kingdom) supplemented with 10%FCS (Lonza, Wuppertal, Germany), 2mM L-glutamine, 1mM sodium pyruvate at 37°C in a humidified atmosphere containing 7.5% CO 2 . CTLs were cultured in α-MEM (Lonza), 10%FCS (PAA, Heidelberg, Germany), 2mM L-glutamine, 1mM sodiumpyruvate, 0.05 mM 2-ME, 5% v/v of 0.5 M methyl-α-D-mannopyranoside and 5% v/v ConA supernatant. ). All animal studies were approved by the Regierungspräsidium, Tübingen, Germany.
Mice and BMT
Histopathology and Immunohistochemistry
Liver, intestin, and skin from the interscapular region were fixed in 4% formalin, paraffinembedded, sectioned and stained with H&E. Slides were coded and examined by a pathologist who was blinded for the experimental history of the animals. Histopathology of GVHD was graded according to Kaplan et al. 25 . To determine target cell apoptosis paraffin sections were stained at room temperature with a polyclonal cleaved caspase-3 (Asp175)
antibody (Cell signaling, Danvers, MA), followed by anti-rabbit biotin (Jackson Immuno
Research, West Grove, PA) and subsequently REAL TM Detection System (Dako, Hamburg, Germany) according to the manufacturer's protocol, nuclear counterlabeled with hemalaun and embedded in Aquatex medium (Merck, Darmstadt, Germany).
Induction of apoptosis
CD95-sensitivity was determined by incubating cells with 100 ng/ml CD95L and 1 µg/ml enhancer of ligands (Alexis Biochemicals, Lörrach, Germany). After 24 hours specific apoptosis was determined by 7-AAD staining on LSRII flow cytometer.
Generation of alloantigen-specific T cells
Spleen cells from B6 mice were weekly stimulated at 1:1 ratio with irradiated spleen cells from B6D2F1 mice as previously described. 7 If indicated, APG101 at a concentration of 100 ng/ml was present during the whole stimulation time. Mice were treated twice a week with a fixed dose of 1 mg APG101/mouse i.p.. Induction of GVHD was determined by weight loss, a clinical scoring system 23 and survival. Due to the toxic effect of irradiation GVHD scores increased and body weight decreased initially between day 4 and 10 after transplantation. After a short recovery phase mice reconstituted with BM and spleen cells exhibited severe weight loss, increased GVHD-scores and a mortality of 38%. Importantly, mice treated with APG101 prophylactically at day -1 and even therapeutically at day 6 showed only a modest weight loss and increase in GVHD-scores and a 100% survival comparable to mice transplanted with BM alone. However, starting treatment 13 days after transplantation APG101 did not prevent GVHD induction ( developed clinical GVHD and showed no improved survival compared to the PBS-treated groups (Suppl. Fig. 1A , B). These data clearly show that CD95L-mediated GVHD can be specifically inhibited by APG101 treatment starting either one day before or six days after transplantation.
APG101 treatment strongly attenuates clinical GVHD in a minor histocompatibility antigen mismatched BMT model
The B6→B6D2F1 BMT model resembles the haploidentical BMT, but in humans transplantations with differences in only miHAgs are more frequently performed. Therefore, we tested the effect of APG101 in a miHAg-mismatched model (B10.D2→BALB/c).
Lethally irradiated BALB/c mice reconstituted with B10.D2-derived TCD BM and spleen cells and treated with PBS developed severe GVHD with increased GVHD scores and a 100% mortality after 41 days. Treatment with APG101 starting one day before transplantation diminished GVHD severity and most importantly rescued mice from lethal GVHD with 60%
( Fig. 3A, B ). Mice transplanted with TCD BM alone and treated with PBS or APG101 survived and exhibited no signs of GVHD. Histological liver GVHD was significantly decreased by APG101 treatment, while skin GVHD was only slightly diminished and no
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 1 3 effect was observed in the intestine (Fig. 3C ). These data show that in two clinically relevant BMT models APG101 attenuated clinical and histological GVHD and most importantly significantly improved the survival of transplanted animals. and APG101-treated mice. All together, these data clearly show that despite the inhibitory effects of APG101 on GVHD, alloantigen-specific T cell function required for tumor cell rejection or early T cell immunity is not impaired by APG101.
APG101 treatment does not
GVT effect is maintained in APG101-treated mice after allogeneic BMT
Since APG101 did not abrogate effector functions of transplanted allogeneic T cells and the CD95/CD95L system may be dispensable for tumor rejection 11, 13 we tested the anti-tumor Most importantly, mice receiving APG101 together with TCD BM and allogeneic spleen cells exhibited a survival of 95% independent whether treatment was started on day -1 or 6 ( For
Discussion
The 
induced GVHD was achieved to some extent with anti-CD95L antibodies or by using CD95L-deficient T cells as allogeneic effector cells. 10,11,13,29 While anti-CD95L antibody treatment reduced morbidity to 50% and was accompanied by a strongly extenuated weight loss, marked hepatic lymphocyte infiltration was still present in antibody-treated mice. 29 In this study CD95L antibody injections were superior to human Fas-Fc treatment. 29 In our experiments, however, APG101 treatment rescued 60 -100% of the mice from GVHDinduced cell death. Inhibition of GVHD was also reported after injections of a non-toxic anti-CD95 antibody mediating apoptosis of transplanted recipient-activated T cells 30 suggesting that interference with the CD95 system in fact is effective in several models.
Defining effector mechanisms for GVHD induction, however, appears to be model system dependent. Contributions of the CD95/CD95L or the perforin/granzyme system to GVHD induction are partially defined by the type of MHC disparities between host and recipient.
While the CD95/CD95L pathway plays a predominant role in CL II mismatches, the perforin/granzyme system contributes efficiently to GVHD induction in Cl I differences.
27,31
APG101 efficiently prevents GVHD in major and minor histocompatibility mismatched models where GVHD development is dependent on the presence of CD4 + T cells in the transplant 31-33 but is inefficient in the B6→B6.bm1 model, in which GVHD induction is preferentially mediated by perforin/granzyme and CD8 + T cells 27, 34, 35 . However, T cell deficiency in perforin and CD95L does not necessarily abrogate GVHD development 36, 37 indicating that other cytotoxic molecules such as TRAIL or TNF-α might also contribute to disease development 10,11,15,37 .
To our knowledge none of the studies analyzed the effect of disrupting CD95/CD95L interaction on anti-tumor cytotoxicity, donor engraftment or T cell effector function. Here, we
show that preventing CD95-mediated apoptosis by APG101 had no effect on the GVT activity of transplanted allogeneic T cells. Independent whether or not mice were treated with APG101, tumor cells were totally eradicated as soon as the transplant contained mature T Since the CD95/CD95L complex is now increasingly recognized as a system which does not only signal apoptosis but also mediates non-apoptotic cell type specific suppression or activation depending on the environment and co-stimulation 18, 20, 40, 41 , we investigated the effect of APG101 on donor engraftment and T cell function and homing. Allogeneic T cells from APG101 treated mice were phenotypically indistinguishable from T cells developing in PBS-injected animals and donor engraftment of CD4 + and CD8 + T, NK, and NK-T cells was similar. Even T reg numbers were identical although these cells are susceptible to homeostatic control by CD95. 42 Although CD95L activation is known to be a possible modulator of T cell expansion 21, 22 , re-isolated allogeneic T cells from APG101 treated mice showed no changes in proliferation towards alloantigen or third party antigens compared to T cells isolated from GVHD suffering mice. T cell expansion in APG101-treated mice was further confirmed by efficient T cell invasion of host tissues in vivo, which was reported to be impaired if CD95L- confirmed by a decrease of active capsase-3-expressing cells in liver and intestine and the inefficiency of APG101 to prevent GVHD in a perforin/granzyme-dependent BMT model.
Since APG101 prevents CD95L-mediated GVHD in murine allogeneic BMT models and does not inhibit the anti-tumor cytotoxicity of allogeneic T cells it might be a potential therapeutic reagent for prevention or even treatment of human GVHD after allogeneic BMT.
However, while murine GVHD models are well defined by their dependence on either the CD95/CD95L or perforin/granzyme system 27 the situation in humans appears to be more complex. Elevated CD95L expression was detected in patients with acute and chronic GVHD, however perforin and granzyme B serum levels were also increased indicating that both effector pathways contribute to human GVHD. [45] [46] [47] [48] Applying APG101 as a mono therapy in humans might therefore not be sufficient for GVHD inhibition and most likely requires the administration of other immunosuppressive drugs.
In summary, we showed that APG101 is an effective therapeutic reagent to prevent CD95L-mediated GVHD but preserves anti-tumor cytotoxicity and early T cell immunity. These data suggest that APG101 could be incorporated into protocols for GVHD prevention and treatment during BMT. For
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